| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Replimune Group, Inc. | Director | Stock Option (right to buy) | 25,200 | 01 Apr 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | 29 Dec 2023 | 0 | $0 | 3 | Director | 29 Dec 2023, 16:30 |
| REPL | Replimune Group, Inc. | 01 Apr 2023 | 1 | $0 | 4 | Director | 04 Apr 2023, 20:04 |
| REPL | Replimune Group, Inc. | 01 Apr 2022 | 1 | $0 | 4 | Director | 05 Apr 2022, 16:10 |
| /report/000095010321019582-slootweg-hugo-alexander-2021-12-09 | Forbion European Acquisition Corp. | 09 Dec 2021 | 0 | $0 | 3 | Director | 09 Dec 2021, 16:43 |